Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 3, 2014, Pages 240-253

  Chang, Xiubao ^a   Zhu, Yuanxiao ^a   Shi, Changxin ^a   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

Author keywords

cancer treatment; cereblon; E3 ubiquitin ligase; immunomodulatory drugs; multiple myeloma

Indexed keywords

AUTACOID; CEREBLON; CYTOKINE; IMMUNOLOGIC FACTOR; UBIQUITIN PROTEIN LIGASE E3;

APOPTOSIS; BIOLOGICAL MODEL; CANCER THERAPY; CELL CYCLE CHECKPOINT; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; HUMAN; IMMUNOMODULATORY DRUGS; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; REVIEW;

CANCER TREATMENT; CEREBLON; E3 UBIQUITIN LIGASE; IMMUNOMODULATORY DRUGS; MULTIPLE MYELOMA;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA;

EID: 84897722338     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt142     Document Type: Review

References (227)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC. Multiple myeloma. Lancet 2009, 374: 324-339.
2. Solly S. Remarks on the pathology of mollities ossium; with cases. Med Chir Trans 1844, 27: 435-461, 498-3-498-8.
3. MacintyreW. Case of Mollities and Fragilitas Ossium, accompanied with urine strongly charged with animal matter.Med Chir Trans 1850, 33: 211-232.
4. Loge JP and Rundles RW. Urethane (ethyl carbamate) therapy in multiple myeloma. Blood 1949, 4: 201-216.
5. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M and Spicka I, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359: 906-917.
6. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O and Kropff M, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010, 28: 2259-2266.
7. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R and Garcia-Larana J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol 2010, 11: 934-941.
8. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM and Hulin C, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91: 1498-1505.
9. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M and Lenain P, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28: 4621-4629.
10. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D and Marit G, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28: 4630-4634.
11. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M and Di Raimondo F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010, 376: 2075-2085.
12. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B and Renaud M, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007, 370: 1209-1218.
13. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ and Stuckey WJ, Jr,, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969, 208: 1680-1685.
14. Seemuller E, Lupas A, Stock D, Lowe J, Huber R and Baumeister W. Proteasome from Thermoplasma acidophilum: A threonine protease. Science 1995, 268: 579-582.
15. Stein RL, Melandri F and Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 1996, 35: 3899-3908.
16. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L and Klunder JM, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998, 8: 333-338.
17. Adams J and Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest 2004, 22: 304-311.
18. D'Amato RJ, Loughnan MS, Flynn E and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91: 4082-4085.
19. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P and Munshi N, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341: 1565-1571.
20. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME and Abonour R, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010, 11: 29-37.
21. Miller MT and Stromland K. Teratogen update: thalidomide: A review, with a focus on ocular findings and new potential uses. Teratology 1999, 60: 306-321.
22. Melchert M and List A. The thalidomide saga. Int J Biochem Cell Biol 2007, 39: 1489-1499.
23. Knobloch J and Ruther U. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 2008, 7: 1121-1127.
24. Haslett P, Tramontana J, Burroughs M, Hempstead M and Kaplan G. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997, 24: 1223-1227.
25. Lovell CR, Hawk JL, Calnan CD and Magnus IA. Thalidomide in actinic prurigo. Br J Dermatol 1983, 108: 467-471.
26. Iyer CG, Languillon J, Ramanujam K, Tarabini-Castellani G, De las Aguas JT, Bechelli LM and Uemura K, et al. WHO co-ordinated shortterm double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971, 45: 719-732.
27. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G and Stirling DI. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996, 39: 3238-3240.
28. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ and Patterson RT, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-Alpha. J Immunol 1999, 163: 380-386.
29. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B and Harousseau J, et al. Prevention of thalidomide- and lenalidomide-Associated thrombosis in myeloma. Leukemia 2008, 22: 414-423.
30. Carrier M, Le Gal G, Tay J, Wu C and Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: A systematic review and meta-Analysis. J Thromb Haemost 2011, 9: 653-663.
31. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J and Wallace P, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-Tumour activity of rituximab in vivo. Br J Haematol 2008, 140: 36-45.
32. Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG and Galustian C. Enhanced cross-priming of naive CD8+ T cells by DCs treated by the IMiDs((R)) immunomodulatory compounds lenalidomide and pomalidomide. Immunology 2013, 139: 377-385. doi:10.1111/imm.12087.
33. Castelli R, Cassin R, Cannavo A and Cugno M. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2013, 13: 1-7.
34. Haslett PA, Corral LG, Albert M and Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998, 187: 1885-1892.
35. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT and Lin B, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98: 210-216.
36. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D and Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-Alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002, 130: 75-84.
37. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP and Wolbring G, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003, 305: 1222-1232.
38. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N and Kumar S, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005, 128: 192-203.
39. Payvandi F, Wu L, Naziruddin SD, Haley M, Parton A, Schafer PH and Chen RS, et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-Theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J Interferon Cytokine Res 2005, 25: 604-616.
40. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N and Mitsiades C, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103: 1787-1790.
41. Hess J, Angel P and Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004, 117: 5965-5973.
42. Gorgun G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M and Cirstea D, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010, 116: 3227-3237.
43. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD and Jagannath S, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108: 618-621.
44. Muthu Raja KR, Kovarova L, Stossova J and Hajek R. Flow cytometric phenotyping and analysis of T regulatory cells in multiple myeloma patients. Klin Onkol 2011, 24(Suppl): S30-S33.
45. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J and Todryk S, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009, 58: 1033-1045.
46. Muthu Raja KR, Kovarova L and Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012, 53: 1406-1408.
47. Gupta R, Ganeshan P, Hakim M, Verma R, Sharma A and Kumar L. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 2011, 35: 874-878.
48. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F and LeBlanc R, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100: 3063-3067.
49. Bartlett JB, Dredge K and Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004, 4: 314-322.
50. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT and Lin B, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15: 1950-1961.
51. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT and Treon SP, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96: 2943-2950.
52. Hicklin DJ and Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23: 1011-1027.
53. Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E and Zhang Y, et al. Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. Int J MolMed 2003, 11: 785-790.
54. Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E and Zhang Y, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatinresistant human lung carcinoma cells. Anticancer Res 2003, 23: 2481-2487.
55. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T and Catley L, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003, 17: 41-44.
56. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GWand Stirling D, et al. Novel thalidomide analogues display anti-Angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87: 1166-1172.
57. Noguchi T, Fujimoto H, Sano H, Miyajima A, Miyachi H and Hashimoto Y. Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett 2005, 15: 5509-5513.
58. Heere-Ress E, Boehm J, Thallinger C, Hoeller C, Wacheck V, Birner P andWolff K, et al. Thalidomide enhances the anti-Tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol 2005, 125: 201-206.
59. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y and Shirley MA, et al. Orally administered lenalidomide (CC-5013) is anti-Angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005, 69: 56-63.
60. Martiniani R, Di Loreto V, Di Sano C, Lombardo A and Liberati AM. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol 2012, 2012: 842945.
61. Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC and Anderson KC. Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007, 101: 950-968.
62. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA and Anderson KC. Multiple myeloma cell adhesioninduced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87: 1104-1112.
63. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM and Serve H, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95: 2630-2636.
64. Hideshima T, Chauhan D, Schlossman R, Richardson P and Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20: 4519-4527.
65. Nishimura K, Hashimoto Y and Iwasaki S. Enhancement of phorbol esterinduced production of tumor necrosis factor alpha by thalidomide. Biochem Biophys Res Commun 1994, 199: 455-460.
66. Shibata Y, Shichita M, Sasaki K, Nishimura K, Hashimoto Y and Iwasaki S. N-Alkylphthalimides: structural requirement of thalidomidal action on 12-O-Tetradecanoylphorbol-13-Acetate-induced tumor necrosis factor alpha production by human leukemia HL-60 cells. Chem Pharm Bull (Tokyo) 1995, 43: 177-179.
67. Xu W, Celeridad M, Sankar S, Webb DR and Bennett BL. CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol 2008, 128: 392-399.
68. Sampaio EP, Sarno EN, Galilly R, Cohn ZA and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173: 699-703.
69. Barnes PF, Chatterjee D, Brennan PJ, Rea TH and Modlin RL. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992, 60: 1441-1446.
70. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177: 1675-1680.
71. Weglicki WB, Stafford RE, Dickens BF, Mak IT, Cassidy MM and Phillips TM. Inhibition of tumor necrosis factor-Alpha by thalidomide in magnesium deficiency. Mol Cell Biochem 1993, 129: 195-200.
72. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S and Johnson B, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995, 1: 384-397.
73. Peterson PK, Hu S, Sheng WS, Kravitz FH, Molitor TW, Chatterjee D and Chao CC. Thalidomide inhibits tumor necrosis factor-Alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995, 172: 1137-1140.
74. Schmidt H, Rush B, Simonian G, Murphy T, Hsieh J and Condon M. Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats. J Surg Res 1996, 63: 143-146.
75. Kroger H, Miesel R, Dietrich A, Ohde M, Rajnavolgyi E and Ockenfels H. Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice. Inflammation 1996, 20: 203-215.
76. Shannon EJ and Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-Alpha by mononuclear cells. Immunopharmacol Immunotoxicol 1996, 18: 59-72.
77. Wnendt S, Finkam M, Winter W, Ossig J, Raabe G and Zwingenberger K. Enantioselective inhibition of TNF-Alpha release by thalidomide and thalidomide-Analogues. Chirality 1996, 8: 390-396.
78. Rosinol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M and Rozman M, et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 2004, 26: 145-148.
79. Vale ML, Cunha FQ, Brito GA, Benevides VM, Ferreira SH, Poole S and Ribeiro RA. Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation. Eur J Pharmacol 2006, 536: 309-317.
80. Moreira AL, Tsenova-Berkova L, Wang J, Laochumroonvorapong P, Freeman S, Freedman VH and Kaplan G. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber Lung Dis 1997, 78: 47-55.
81. Moreira AL, Wang J, Sarno EN and Kaplan G. Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res 1997, 30: 1199-1207.
82. Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW and Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998, 40: 11-20.
83. Dmoszynska A, Rolinski J, Bojarska-Junak A, Manko J, Jawniak D, Walter-Croneck A and Soroka-Wojtaszko M, et al. Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-Term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients. Pol J Pharmacol 2001, 53: 709-713.
84. Thiele A, Bang R, Gutschow M, Rossol M, Loos S, Eger K and Tiegs G, et al. Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide. Eur J Pharmacol 2002, 453: 325-334.
85. Li J, Luo SK, Hong WD and Huang JQ. In vitro inhibition and mechanism of multiple myeloma cells growth by thalidomide. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002, 10: 70-72.
86. Li J, Luo S, Hong W, Zhou Z and Zou W. Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients. Zhonghua Zhong Liu Za Zhi 2002, 24: 254-256.
87. Qian S, Somlo G, Zhou B and Yen Y. Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3. Ther Clin Risk Manag 2005, 1: 231-241.
88. Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N and Hamasaki M, et al. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia 2005, 19: 1253-1261.
89. Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M and Nakano T, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007, 179: 708-714.
90. Shannon E, Noveck R, Sandoval F, Kamath B and Kearney M. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-Alpha in volunteers with experimental endotoxemia. Transl Res 2007, 150: 275-280.
91. Choe JY, Jung HJ, Park KY, Kum YS, Song GG, Hyun DS and Park SH, et al. Anti-fibrotic effect of thalidomide through inhibiting TGF-betainduced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010, 59: 177-188.
92. Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessi M and Panzone F, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010, 15: 200-211.
93. Mantovani G. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. Eur Rev Med Pharmacol Sci 2010, 14: 292-301.
94. Chaulet C, Croix C, Alagille D, Normand S, Delwail A, Favot L and Lecron JC, et al. Design, synthesis and biological evaluation of new thalidomide analogues as TNF-Alpha and IL-6 production inhibitors. Bioorg Med Chem Lett 2011, 21: 1019-1022.
95. Ch'ang HJ, Hsu C, Chen CH, Chang YH, Chang JS and Chen LT. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012, 82: 817-825.
96. Melo CM, Morais TC, Tome AR, Brito GA, Chaves MH, Rao VS and Santos FA. Anti-inflammatory effect of alpha,beta-Amyrin, a triterpene from Protium heptaphyllum, on cerulein-induced acute pancreatitis in mice. Inflamm Res 2011, 60: 673-681.
97. Zhang C, Zhang X, Ma L, Peng F, Huang J and Han H. Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy. Endocrine 2012, 41: 248-255.
98. Mazzoccoli L, Cadoso SH, Amarante GW, de Souza MV, Domingues R, Machado MA and de Almeida MV, et al. Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10. Biomed Pharmacother 2012, 66: 323-329.
99. Puzik A, Thiel A, Faust K and Hartel C. Thalidomide has antiinflammatory properties in neonatal immune cells. Innate Immun 2013, 19: 42-52.
100. Amirshahrokhi K and Ghazi-Khansari M. Thalidomide attenuates multiple low-dose streptozotocin-induced diabetes in mice by inhibition of proinflammatory cytokines. Cytokine 2012, 60: 522-527.
101. Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Lagana C, Rigolino C and Morabito F, et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol 2013, 92: 25-32.
102. Li D, Xu LY, Chang ZJ, Zhao GJ, Nan C and Lu ZQ. Effect of thalidomide in a mouse model of paraquat-induced acute lung injury and the underlying mechanisms. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2013, 31: 178-183.
103. Geist C, Wohrmann T, Schneider J and Zwingenberger K. Effects of thalidomide on the local Shwartzman reaction in mice and rabbits. FEMS Immunol Med Microbiol 1995, 12: 165-174.
104. Geitz H, Handt S and Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996, 31: 213-221.
105. Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF and Taylor LD. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-Alpha agent thalidomide. Cell Mol Biol (Noisy-le-grand) 2001, 47: 1105-1114.
106. Li J, Luo SK, Hong WD, Zhou ZH and Zou WY. Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma. Ai Zheng 2003, 22: 346-349.
107. Zeldis JB, Schafer PH, Bennett BL, Mercurio F and Stirling DI. Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol 2003, 30: 275-281.
108. Lv P, Paul SC, Xiao Y, Liu S and Luo H. Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. Mediators Inflamm 2006, 2006: 93253.
109. Lin YC, Shun CT,Wu MS and Chen CC. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 2006, 12: 7165-7173.
110. Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM and Zhou YH. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res 2007, 38: 15-27.
111. Guirgis AA, Zahran MA, Mohamed AS, Talaat RM, Abdou BY and Agwa HS. Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression. Int Immunopharmacol 2010, 10: 806-811.
112. Kim DH, Kim YJ, Chang SA, Lee HW, Kim HN, Kim HK and Chang HJ, et al. The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy. Eur J Heart Fail 2010, 12: 1051-1060.
113. Zhang Y, Yang M, Yang Y, Zheng SL, Cai Y, Xia P and Chen WW, et al. Thalidomide attenuates graft arteriosclerosis of aortic transplant in a rat model. Transplant Proc 2011, 43: 2022-2026.
114. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS and Muller GW, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-Alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 2004, 230: 81-88.
115. Fujimoto H, Noguchi T, Kobayashi H, Miyachi H and Hashimoto Y. Effects of immunomodulatory derivatives of thalidomide (IMiDs) and their analogs on cell-differentiation, cyclooxygenase activity and angiogenesis. Chem Pharm Bull (Tokyo) 2006, 54: 855-860.
116. Anderson KC. Lenalidomide and thalidomide: mechanisms of action- similarities and differences. Semin Hematol 2005, 42: S3-S8.
117. Moreira AL, Friedlander DR, Shif B, Kaplan G and Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 1999, 43: 109-114.
118. Keifer JA, Guttridge DC, Ashburner BP and Baldwin AS, Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001, 276: 22382-22387.
119. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T and Munshi NC, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99: 4525-4530.
120. Hansen JM, Gong SG, Philbert M and Harris C. Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Dev Dyn 2002, 225: 186-194.
121. DeCicco KL, Tanaka T, Andreola F and De Luca LM. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway. Carcinogenesis 2004, 25: 1805-1812.
122. Yagyu T, Kobayashi H, Matsuzaki H, Wakahara K, Kondo T, Kurita N and Sekino H, et al. Thalidomide inhibits tumor necrosis factoralpha- induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab 2005, 90: 3017-3021.
123. Pereira RM, Calegari-Silva TC, Hernandez MO, Saliba AM, Redner P, Pessolani MC and Sarno EN, et al. Mycobacterium leprae induces NF-kappaB-dependent transcription repression in human Schwann cells. Biochem Biophys Res Commun 2005, 335: 20-26.
124. Kobayashi H, Yagyu T, Kondo T, Kurita N, Inagaki K, Haruta S and Kawaguchi R, et al. Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination. Cancer Res 2005, 65: 10464-10471.
125. Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, Cui W and Ponciano-Jackson D, et al. Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 2006, 108: 4126-4135.
126. Paul SC, Lv P, Xiao YJ, An P, Liu SQ and Luo HS. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-Alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB. Pathobiology 2006, 73: 82-92.
127. Lv P, Luo HS, Zhou XP, Chireyath Paul S, Xiao YJ, Si XM and Liu SQ. Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress. Pathol Res Pract 2006, 202: 777-788.
128. Genovese T, Mazzon E, Esposito E, Di Paola R, Caminiti R, Meli R and Bramanti P, et al. Effect of thalidomide on signal transduction pathways and secondary damage in experimental spinal cord trauma. Shock 2008, 30: 231-240.
129. Ge Y, Byun JS, De Luca P, Gueron G, Yabe IM, Sadiq-Ali SG and Figg WD, et al. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro- phenyl)-4,5,6,7-Tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol. Mol Pharmacol 2008, 74: 872-883.
130. Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y and Sun B. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res 2008, 27: 60.
131. Noman AS, Koide N, Hassan F, Iftakhar-E-Khuda I, Dagvadorj J, Tumurkhuu G and Islam S, et al. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-Alpha production via down-regulation of MyD88 expression. Innate Immun 2009, 15: 33-41.
132. Noman AS, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y and Komatsu T, et al. Thalidomide inhibits lipopolysaccharide-induced nitric oxide production and prevents lipopolysaccharide-mediated lethality in mice. FEMS Immunol MedMicrobiol 2009, 56: 204-211.
133. Mondello S, Mazzon E, Di Paola R, Crisafulli C, Mondello P, Buemi M and Aloisi C, et al. Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model. Shock 2009, 32: 332-339.
134. Dong ZZ, Yao DF, Wu W, Yao M, Yu HB, Shen JJ and Qiu LW, et al. Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats. Hepatobiliary Pancreat Dis Int 2010, 9: 169-174.
135. Knobloch J, Jungck D and Koch A. Apoptosis induction by thalidomide: critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis? Curr Mol Pharmacol 2011, 4: 26-61.
136. Hernandez Mde O, Fulco Tde O, Pinheiro RO, Pereira Rde M, Redner P, Sarno EN and Lopes UG, et al. Thalidomide modulates Mycobacterium leprae-induced NF-kappaB pathway and lower cytokine response. Eur J Pharmacol 2011, 670: 272-279.
137. Rance E, Tanner JE and Alfieri C. Inhibition of IkappaB kinase by thalidomide increases hepatitis C virus RNA replication. J Viral Hepat 2012, 19: e73-e80.
138. Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T and Lugering N. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 2004, 172: 5103-5109.
139. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C and Podar K, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004, 104: 4188-4193.
140. Knobloch J, Schmitz I, Gotz K, Schulze-Osthoff K and Ruther U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 2008, 28: 529-538.
141. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW and Chen RS, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009, 77: 78-86.
142. Gao S, Yang XJ, Zhang WG, Ji YW and Pan Q. Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J (Engl) 2009, 122: 1260-1266.
143. Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R and Binion DG. Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol 2010, 298: G167-G176.
144. Cosenza M, Civallero M, Grisendi G, Marcheselli L, Roat E, Bari A and Sacchi S. Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Ann Hematol 2012, 91: 1613-1622.
145. Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M and Galson DL, et al. IMiD immunomodulatory compounds block C/EBPfbetag translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011, 117: 5157-5165.
146. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao Wand Powell J, et al. IRF4 addiction in multiple myeloma. Nature 2008, 454: 226-231.
147. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H and Bartlett JB, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011, 154: 325-336.
148. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S and Chang XB, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118: 4771-4779.
149. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J and Karasawa S, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26: 2326-2335.
150. Yang Y, Nie F, Xu D, Luo J, Zhuang Y and Pan Y. A multimedia retrieval framework based on semi-supervised ranking and relevance feedback. IEEE Trans Pattern Anal Mach Intell 2012, 34: 723-742.
151. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH and Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013, 160: 487-502.
152. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH and Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 1997, 94: 10057-10062.
153. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R and Ciliberto G, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10: 105-115.
154. Puthier D, Bataille R and Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999, 29: 3945-3950.
155. Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G and Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003, 22: 2950-2959.
156. Ezell TN, Maloney N, Githua JW and Taylor LD. Exposure to the anti-TNF-Alpha drug thalidomide induces apoptotic cell death in human T leukemic cells. Cell Mol Biol (Noisy-le-grand) 2003, 49: 1117-1124.
157. Fujita K, Asami Y, Tanaka K, Akita M and Merker HJ. Anti-Angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta. Histochem Cell Biol 2004, 122: 27-33.
158. Zhang M, Abe Y, Matsushima T, Nishimura J, Nawata H and Muta K. Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. Leuk Lymphoma 2005, 46: 425-433.
159. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK and Taube T, et al. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 2006, 12: 5526-5532.
160. Iguchi T, Yachide-Noguchi T, Hashimoto Y, Nakazato S, Sagawa M, Ikeda Y and Kizaki M. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide. Int J Mol Med 2008, 21: 163-168.
161. Liu KH, Liao LM, Ro LS, Wu YL and Yeh TS. Thalidomide attenuates tumor growth and preserves fast-Twitch skeletal muscle fibers in cholangiocarcinoma rats. Surgery 2008, 143: 375-383.
162. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB and Yi Q, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009, 84: 553-559.
163. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA and Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010, 115: 834-845.
164. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH and Mendy D, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10: 155-167.
165. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q and Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011, 35: 380-386.
166. Jinesh GG, Lee EK, Tran J and Kamat AM. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urol Oncol 2013, 31: 1676-1682.
167. Slawinska-Brych A, Zdzisinska B, Mizerska-Dudka M and Kefer- Szerszen M. Induction of apoptosis in multiple myeloma cells by a statin-Thalidomide combination can be enhanced by p38 MAPK inhibition. Leuk Res 2013, 37: 586-594.
168. Kuroda Y, Sakai A, Tsuyama N, Katayama Y, Munemasa S, Asaoku H and Okikawa Y, et al. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma. Int J Oncol 2008, 33: 1201-1213.
169. Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW and Schafer P, et al. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res 2003, 63: 593-599.
170. Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A and di Gaudio F, et al. NF-kappaB protects Behcet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 2005, 52: 2179-2191.
171. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K and Schafer PH, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67: 746-755.
172. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH and Muller GW, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69: 7347-7356.
173. Yata K, Otsuki T, Kurebayashi J, Uno M, Fujii T, Yawata Y and Takata A, et al. Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells. Int J Oncol 2003, 22: 165-173.
174. Hattori Y and Iguchi T. Thalidomide for the treatment of multiple myeloma. Congenit Anom (Kyoto) 2004, 44: 125-136.
175. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH and Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006, 30: 849-858.
176. Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J and Freeman D, et al. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther 2006, 5: 450-456.
177. Styczynski J, Czyzewski K and Wysocki M. Ex vivo activity of thalidomide in childhood acute leukemia. Leuk Lymphoma 2006, 47: 1123-1128.
178. Czyzewski K, Zaborowska A and Styczynski J. Thalidomide increases in vitro sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and cytarabine. Arch Immunol Ther Exp (Warsz) 2006, 54: 341-345.
179. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q and Byrd J, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009, 106: 12974-12979.
180. Komrokji RS and List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am 2010, 24: 377-388.
181. Dawar R and Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best Pract Res Clin Haematol 2012, 25: 185-190.
182. Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GWand Stirling DI, et al. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med 2007, 5: 38.
183. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL and Arlen P, et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007, 99: 1047-1055.
184. Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG and Galustian C. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 2009, 101: 803-812.
185. Maria de Souza C, Fonseca de Carvalho L, da Silva Vieira T, Candida Araujo ESA, Teresa Paz Lopes M, Alves Neves Diniz Ferreira M and Passos Andrade S, et al. Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. Biomed Pharmacother 2012, 66: 491-498.
186. Lin F, Cao J, Huang Z, Pei Z, Gu W, Fan S and Li K, et al. Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice. Exp Ther Med 2013, 5: 1403-1407.
187. Gelati M, Corsini E, Frigerio S, Pollo B, Broggi G, Croci D and Silvani A, et al. Effects of thalidomide on parameters involved in angiogenesis: An in vitro study. J Neurooncol 2003, 64: 193-201.
188. Amin EA and Welsh WJ. A preliminary in silico lead series of 2-phthalimidinoglutaric acid analogues designed as MMP-3 inhibitors. J Chem Inf Model 2006, 46: 2104-2109.
189. Gordon JN, Prothero JD, Thornton CA, Pickard KM, Di Sabatino A, Goggin PM and Pender SL, et al. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-Alpha and MMP-3 production in patients with inflammatory bowel disease. JCC 2009, 3: 175-182.
190. Segarra M, Lozano E, Corbera-Bellalta M, Vilardell C, Cibeira MT, Esparza J and Izco N, et al. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica 2010, 95: 456-463.
191. Fougere M, Gaudineau B, Barbier J, Guaddachi F, Feugeas JP, Auboeuf D and Jauliac S. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene 2010, 29: 2292-2301.
192. Neubert R, Nogueira AC and Neubert D. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993, 67: 1-17.
193. Nogueira AC, Neubert R, Helge H and Neubert D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994, 55: 77-92.
194. Neubert R, Hinz N, Thiel R and Neubert D. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 1996, 58: 295-316.
195. McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997, 49: 123-131.
196. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C and Chauhan D, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22: 1925-1932.
197. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y and Yamaguchi Y, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327: 1345-1350.
198. Ito T, Ando H and Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci 2011, 68: 1569-1579.
199. Ito T and Handa H. Deciphering the mystery of thalidomide teratogenicity. Congenit Anom (Kyoto) 2012, 52: 1-7.
200. Chang XB and Stewart AK. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol 2011, 2: 287-294.
201. Nag A, Bondar T, Shiv S and Raychaudhuri P. The xeroderma pigmentosum group E gene product DDB2 is a specific target of cullin 4A in mammalian cells. Mol Cell Biol 2001, 21: 6738-6747.
202. Chen X, Zhang Y, Douglas L and Zhou P. UV-damaged DNA-binding proteins are targets of CUL-4A-mediated ubiquitination and degradation. J Biol Chem 2001, 276: 48175-48182.
203. Sugasawa K, Okuda Y, Saijo M, Nishi R, Matsuda N, Chu G and Mori T, et al. UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 2005, 121: 387-400.
204. Groisman R, Kuraoka I, Chevallier O, Gaye N, Magnaldo T, Tanaka K and Kisselev AF, et al. CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes Dev 2006, 20: 1429-1434.
205. Groisman R, Polanowska J, Kuraoka I, Sawada J, Saijo M, Drapkin R and Kisselev AF, et al. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 2003, 113: 357-367.
206. Kapetanaki MG, Guerrero-Santoro J, Bisi DC, Hsieh CL, Rapic-Otrin V and Levine AS. The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. Proc Natl Acad Sci USA 2006, 103: 2588-2593.
207. Wang H, Zhai L, Xu J, Joo HY, Jackson S, Erdjument-Bromage H and Tempst P, et al. Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell 2006, 22: 383-394.
208. Liu C, Powell KA, Mundt K, Wu L, Carr AM and Caspari T. Cop9/signalosome subunits and Pcu4 regulate ribonucleotide reductase by both checkpoint-dependent and -independent mechanisms. Genes Dev 2003, 17: 1130-1140.
209. Higa LA, Mihaylov IS, Banks DP, Zheng J and Zhang H. Radiationmediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 2003, 5: 1008-1015.
210. Hu J, McCall CM, Ohta T and Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat Cell Biol 2004, 6: 1003-1009.
211. Bondar T, Ponomarev A and Raychaudhuri P. Ddb1 is required for the proteolysis of the Schizosaccharomyces pombe replication inhibitor Spd1 during S phase and after DNA damage. J Biol Chem 2004, 279: 9937-9943.
212. Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ and Dixit VM. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 2004, 303: 1371-1374.
213. Liu C, Poitelea M, Watson A, Yoshida SH, Shimoda C, Holmberg C and Nielsen O, et al. Transactivation of Schizosaccharomyces pombe cdt2+ stimulates a Pcu4-Ddb1-CSN ubiquitin ligase. EMBO J 2005, 24: 3940-3951.
214. Angers S, Li T, Yi X, MacCoss MJ, Moon RT and Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 2006, 443: 590-593.
215. Lee J and Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell 2007, 26: 775-780.
216. Zimmerman ES, Schulman BA and Zheng N. Structural assembly of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol 2010, 20: 714-721.
217. Jo S, Lee KH, Song S, Jung YK and Park CS. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-Activated potassium channel in rat brain. J Neurochem 2005, 94: 1212-1224.
218. Higgins JJ, Tal AL, Sun X, Hauck SC, Hao J, Kosofosky BE and Rajadhyaksha AM. Temporal and spatial mouse brain expression of cereblon, an ionic channel regulator involved in human intelligence. J Neurogenet 2010, 24: 18-26.
219. Hohberger B and Enz R. Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett 2009, 583: 633-637.
220. Lee KM, Jo S, Kim H, Lee J and Park CS. Functional modulation of AMP-Activated protein kinase by cereblon. Biochim Biophys Acta 2011, 1813: 448-455.
221. Yang Y, Shaffer AL, III, Emre NC, Ceribelli M, Zhang M, Wright G and Xiao W, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21: 723-737.
222. Stewart AK. Novel therapies for relapsed myeloma. Hematology Am Soc Hematol Educ Program 2009: 578-586.
223. Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M and Pfeifer S, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013, 161: 695-700.
224. Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U and Zweegman S, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013, 121: 624-627.
225. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM and Wang M, et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011, 286: 11009-11020.
226. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H and Yang J, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 2013, doi:10.1038/leu.2013.174. [Epub ahead of print].
227. Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F and Lu J, et al. Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl) 2012, 90: 1121-1132.